ArticleFrontiers in immunology2022
Prognostic Role of NLR, PLR and MHR in Patients With Idiopathic Pulmonary Fibrosis.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- A meta-analysis of the clinical significance of neutrophil-to-lymphocyte ratios in interstitial lung disease.PloS one · 2023Pooled it
- Construction and validation of an acute exacerbation risk score for fibrotic idiopathic interstitial pneumonia.Journal of thoracic disease · 2026Article
- A Nomogram Model for Early Mortality Risk Stratification in Elderly Patients with Idiopathic Pulmonary Fibrosis: An Integrative Analysis of Serum Biomarkers and Pulmonary Function Parameters.Journal of clinical medicine · 2026Article
- Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease.BMC pulmonary medicine · 2026Article
- Article
- Linear association between the systemic immune-inflammation index and all-cause mortality in patients with interstitial lung disease: a retrospective cohort study.Frontiers in medicine · 2026Article
- Development and Validation of a Clinical Scoring System Predicting 30-Day Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.Respirology (Carlton, Vic.) · 2025Article
- A Simple Ratio in a Complex Disease: Exploring the Neutrophil-to-Lymphocyte Ratio in Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2025Review
- Predictive role of inflammatory markers in characterizing the progression of interstitial lung disease: a retrospective analysis.American journal of translational research · 2025Article
- Neutrophils as key drivers of pulmonary fibrosis: unveiling mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- Article
- Exploring the Role of Hemogram-Derived Ratios and Liver Fibrosis Scores in Pulmonary Fibrosis.Medicina (Kaunas, Lithuania) · 2024Article
- Predictive factors of mortality in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a novel prognostic scoring system.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Ischemia-Modified Albumin (IMA) Is Associated with Poor Survival in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF): A Pilot Study.Antioxidants (Basel, Switzerland) · 2024Article
- Predictive and Diagnostic Values of Systemic Inflammatory Indices in Bronchopulmonary Dysplasia.Children (Basel, Switzerland) · 2023Article
- Neutrophil-to-Lymphocyte Ratio in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2023Article
- Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease.Clinical rheumatology · 2023Article
- Acute Exacerbations of Interstitial Lung Diseases: Focus on Biomarkers.International journal of molecular sciences · 2023Review
- Analysis of platelet and monocyte-to-lymphocyte ratio and diabetes mellitus with benign prostatic enlargement.Frontiers in immunology · 2023Article
- Genes related to N6-methyladenosine in the diagnosis and prognosis of idiopathic pulmonary fibrosis.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease with low survival time. Since the pathophysiological progression of IPF is closely associated with immunological and inflammatory responses, immune biomarkers, including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and monocyte-high density lipoprotein ratio (MHR), have the potential to predict overall survival in IPF patients. Methods: A total of 278 patients with IPF were finally enrolled. The demographic and clinical characteristics of the patients at baseline were recorded. Multivariable Cox regression analysis was used to evaluate the association between the three biomarkers and overall survival in both the total cohort and acute exacerbation subgroup. Results: The median follow-up was 5.84 months. After adjusting for confounders, we found that only elevated NLR was associated with worse overall survival (OR = 1.019, 95% CI 1.001-1.037, Conclusions: Our results indicated that elevated NLR expression is associated with shorter overall survival in IPF patients, which is independent of other prognostic factors. The NLR may be regarded as a reliable prognostic biomarker for IPF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.